Roughly 12,340 people will be diagnosed with cervical cancer this year, according to American Cancer Society estimates. Development-stage biotech company Advaxis is focused on developing immunotherapies for various cancers and infectious disease, including cervical cancer.
The company’s ADXS-HPV (ADXS11-001) is a therapeutic vaccine for the treatment of women who have already developed cervical cancer as a result of human papilloma virus (HPV) infection, which is also related to a number of cancers, including other genital cancers and some head and neck cancers.
Advaxis’ ADXS11-001 vaccine is currently being developed to help the body build an effective immune response to kill tumor cells. The candidate is undergoing phase II clinical trials for the purpose of evaluating side effects and the efficacy of the vaccine in patients with persistent or recurrent cervical cancer.
As of May 17, 2013, Advaxis had completed enrollment and 110 patients had received 264 doses of ADXS11-001. The company reported final 12-month overall survival at 36 percent with a current 18-month survival of 22 percent, marking the best results yet for this study. The most recent data compare to data from the last update at 33 percent and 17 percent, respectively.
The company estimates primary completion of the phase II study in October 2013.
Advaxis’ clinical pipeline also includes: ADXS-PSA, currently in pre-clinical development for the treatment of prostate cancer; and ADXS-cHER2, currently in pre-clinical development for the treatment of HER2 over-expressing cancers, and in a phase 1 veterinary trial for canine osteosarcoma in large breed companion dogs.
For more information, visit www.advaxis.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment